Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis

被引：0

作者：

Van Der Meeren, Olivier ^{[1
]}

Crasta, Priya ^{[2
]}

Cheuvart, Brigitte ^{[1
]}

De Ridder, Marc ^{[1
]}

机构：

[1] GSK Vaccines, Wavre, Belgium

[2] GSK Vaccines, Bangalore, Karnataka, India

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2015年 / 11卷 / 07期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

页码：1726 / 1728

页数：3

共 50 条

[41] INTRAMUSCULAR VERSUS INTRADERMAL ADMINISTRATION OF A RECOMBINANT HEPATITIS-B VACCINE - A COMPARISON OF RESPONSE RATES AND ANALYSIS OF FACTORS INFLUENCING THE ANTIBODY-RESPONSE
STRUVE, J
ARONSSON, B
FRENNING, B
GRANATH, F
VONSYDOW, M
WEILAND, O
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1992, 24 (04) : 423 - 429
[42] ANALYSIS OF ANTIBODY-PRODUCTION TO VACCINIA VIRUS IN MAN AND RABBITS IN RESPONSE TO INOCULATION OF A RECOMBINANT VACCINIA-HEPATITIS-B VACCINE
CHELYAPOV, NV
CHERNOS, VI
ANDZHAPARIDZE, OG
VOPROSY VIRUSOLOGII, 1988, (02) : 175 - 179
[43] Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age
Janssen, Julia M.
Jackson, Sam
Heyward, William L.
Janssen, Robert S.
VACCINE, 2015, 33 (31) : 3614 - 3618
[44] Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-4018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age
Heyward, William L.
Kyle, Michael
Blumenau, Joseph
Davis, Matthew
Reisinger, Keith
Kabongo, Martin L.
Bennett, Sean
Janssen, Robert S.
Namini, Hamid
Martin, J. Tyler
VACCINE, 2013, 31 (46) : 5300 - 5305
[45] Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease
Fabrizi, F
Martin, P
Dixit, V
Bunnapradist, S
Dulai, G
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (10) : 1053 - 1062
[46] A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix™-B in healthy young adults
Levie, K
Gjorup, I
Skinhoj, P
Stoffel, M
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2002, 34 (08) : 610 - 614
[47] IMMUNOGENICITY AND EFFICACY OF A RECOMBINANT-DNA HEPATITIS-B VACCINE, GENHEVAC-B PASTEUR IN HIGH-RISK NEONATES, SCHOOL-CHILDREN AND HEALTHY-ADULTS
ASSATEERAWATT, A
TANPHAICHITR, VS
SUVATTE, V
YODTHONG, S
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, 1993, 11 (01): : 85 - 91
[48] Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years
Tregnaghi, Miguel W.
Voelker, Ricardo
Santos-Lima, Eduardo
Zambrano, Betzana
VACCINE, 2010, 28 (20) : 3595 - 3601
[49] Analysis of T-cell receptor beta chain variable gene segment usage in healthy adult responders and nonresponders to recombinant hepatitis B vaccine
Soroosh, P
Shokri, F
Azizi, M
Jeddi-Tehrani, M
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2003, 57 (05) : 423 - 431
[50] Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults
Raz, R
Koren, R
Bass, D
ISRAEL MEDICAL ASSOCIATION JOURNAL, 2001, 3 (05): : 328 - 332

← 1 2 3 4 5 →